A phase II, multicenter, open-label, randomized trial investigating SM-88 for the treatment of pancreatic cancer
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2017
At a glance
- Drugs SM 88 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 19 Dec 2017 According to a Tyme Technologies media release, this trial is planned for initiation in the first quarter of 2018.
- 13 Apr 2016 New trial record
- 11 Apr 2016 According to a Tyme Technologies media release, this trial is expected to start in 2016.